• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

New strategy for suppressing the growth of lung cancer cells harboring mutations in the ATP-binding region of EGFR by targeting the molecular motor MYO1D.

作者信息

Ko Yoo-Seung, Kang Hyuno, Bae Jeong A, Kim Sung Jin, Kim Nacksung, Chung Ik Joo, Moon Kyung-Sub, Rho Jin Kyung, Kim Hangun, Ha Hyung-Ho, Oh In-Jae, Kim Kyung Keun

机构信息

Department of Pharmacology, Chonnam National University Medical School, Hwasun, 58128, Korea.

Combinatorial Tumor Immunotherapy MRC, Chonnam National University Medical School, Hwasun, 58128, Korea.

出版信息

Clin Transl Med. 2021 Aug;11(8):e515. doi: 10.1002/ctm2.515.

DOI:10.1002/ctm2.515
PMID:34459138
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8343539/
Abstract
摘要

相似文献

1
New strategy for suppressing the growth of lung cancer cells harboring mutations in the ATP-binding region of EGFR by targeting the molecular motor MYO1D.通过靶向分子马达MYO1D抑制在表皮生长因子受体（EGFR）的ATP结合区域发生突变的肺癌细胞生长的新策略。
Clin Transl Med. 2021 Aug;11(8):e515. doi: 10.1002/ctm2.515.
2
ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.ERK 抑制可有效克服表皮生长因子受体突变型非小细胞肺癌细胞对奥希替尼的获得性耐药。
Cancer. 2020 Mar 15;126(6):1339-1350. doi: 10.1002/cncr.32655. Epub 2019 Dec 10.
3
Acquired EGFR L718V Mutation and Loss of T790M-Mediated Resistance to Osimertinib in a Patient With NSCLC Who Responded to Afatinib.一名对阿法替尼有反应的非小细胞肺癌患者出现获得性表皮生长因子受体（EGFR）L718V突变及T790M介导的奥希替尼耐药性丧失
J Thorac Oncol. 2019 Dec;14(12):e274-e275. doi: 10.1016/j.jtho.2019.07.018.
4
Uncommon EGFR G724S mutations arise in non-small-cell lung cancer patients with acquired resistance to first-generation EGFR-TKIs.罕见的表皮生长因子受体（EGFR）G724S突变出现在对第一代EGFR酪氨酸激酶抑制剂产生获得性耐药的非小细胞肺癌患者中。
Lung Cancer. 2018 Apr;118:173-175. doi: 10.1016/j.lungcan.2018.02.016. Epub 2018 Mar 2.
5
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.获得性 EGFR L718V 突变介导非小细胞肺癌对奥希替尼的耐药性，但保留对阿法替尼的敏感性。
Lung Cancer. 2018 Apr;118:1-5. doi: 10.1016/j.lungcan.2018.01.015. Epub 2018 Jan 31.
6
Response to First-Line Osimertinib Treatment in Non-Small-Cell Lung Cancer With Coexisting G719A and Primary T790M Epidermal Growth Factor Receptor Mutations.伴有G719A和原发性T790M表皮生长因子受体突变的非小细胞肺癌对一线奥希替尼治疗的反应
Clin Lung Cancer. 2019 Jul;20(4):e531-e533. doi: 10.1016/j.cllc.2019.05.002. Epub 2019 May 11.
7
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.阿法替尼或奥希替尼联合西妥昔单抗治疗表皮生长因子受体外显子 20 插入突变型非小细胞肺癌的疗效。
Lung Cancer. 2019 Jan;127:146-152. doi: 10.1016/j.lungcan.2018.11.039. Epub 2018 Nov 29.
8
Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.一线阿法替尼治疗后 EGFR 突变阳性非小细胞肺癌患者的后续治疗方案测序。
Lung Cancer. 2019 Jun;132:126-131. doi: 10.1016/j.lungcan.2019.04.014. Epub 2019 Apr 10.
9
Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.通过血液活检确定对奥希替尼的耐药机制。
Clin Lung Cancer. 2019 Nov;20(6):e597-e600. doi: 10.1016/j.cllc.2019.08.002. Epub 2019 Aug 26.
10
Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.奥希替尼在一名伴有软脑膜转移和EGFR罕见S768I突变患者中的疗效。
Lung Cancer. 2020 May;143:95-96. doi: 10.1016/j.lungcan.2020.03.016. Epub 2020 Mar 18.

引用本文的文献

1
QiDongNing induces lung cancer cell apoptosis via triggering P53/DRP1-mediated mitochondrial fission.齐冬宁通过触发 P53/DRP1 介导的线粒体分裂诱导肺癌细胞凋亡。
J Cell Mol Med. 2024 May;28(9):e18353. doi: 10.1111/jcmm.18353.
2
Identification and validation of neutrophils-related subtypes and prognosis model in triple negative breast cancer.三阴性乳腺癌中性粒细胞相关亚型的鉴定和验证及其预后模型的建立。
J Cancer Res Clin Oncol. 2024 Mar 21;150(3):149. doi: 10.1007/s00432-024-05651-3.
3
A peptide interfering with the dimerization of oncogenic KITENIN protein and its stability suppresses colorectal tumour progression.

本文引用的文献

1
Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.CDK7 抑制剂对非小细胞肺癌细胞系中 EMT 相关的第三代 EGFR-TKIs 耐药性的疗效。
Cells. 2020 Dec 3;9(12):2596. doi: 10.3390/cells9122596.
2
MYO1D binds with kinase domain of the EGFR family to anchor them to plasma membrane before their activation and contributes carcinogenesis.肌球蛋白 1D（MYO1D）与表皮生长因子受体（EGFR）家族的激酶结构域结合，在其激活之前将它们锚定在质膜上，并促进致癌作用。
Oncogene. 2019 Dec;38(49):7416-7432. doi: 10.1038/s41388-019-0954-8. Epub 2019 Aug 16.
3
Oligosaccharyltransferase Inhibition Overcomes Therapeutic Resistance to EGFR Tyrosine Kinase Inhibitors.
一种干扰致癌性 KITENIN 蛋白二聚化及其稳定性的肽可抑制结直肠肿瘤的进展。
Clin Transl Med. 2022 Jul;12(7):e871. doi: 10.1002/ctm2.871.
4
Upregulated SPAG6 promotes acute myeloid leukemia progression through MYO1D that regulates the EGFR family expression.上调的 SPAG6 通过调节 EGFR 家族表达促进急性髓系白血病进展。
Blood Adv. 2022 Sep 27;6(18):5379-5394. doi: 10.1182/bloodadvances.2021006920.
寡糖基转移酶抑制克服了对表皮生长因子受体酪氨酸激酶抑制剂的治疗抵抗。
Cancer Res. 2018 Sep 1;78(17):5094-5106. doi: 10.1158/0008-5472.CAN-18-0505. Epub 2018 Jul 19.
4
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer.晚期非小细胞肺癌中表皮生长因子受体酪氨酸激酶抑制剂靶向治疗获得性耐药的管理。
Mol Cancer. 2018 Feb 19;17(1):38. doi: 10.1186/s12943-018-0777-1.
5
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.表皮生长因子受体异质性及其对胶质母细胞瘤治疗干预的意义。
Neuro Oncol. 2018 May 18;20(6):743-752. doi: 10.1093/neuonc/nox191.
6
Clinical potential of gene mutations in lung cancer.肺癌基因突变的临床潜力
Clin Transl Med. 2015 Dec;4(1):33. doi: 10.1186/s40169-015-0074-1. Epub 2015 Nov 24.
7
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.获得性表皮生长因子受体（EGFR）C797S突变介导携带EGFR T790M的非小细胞肺癌对AZD9291耐药。
Nat Med. 2015 Jun;21(6):560-2. doi: 10.1038/nm.3854. Epub 2015 May 4.
8
Cell surface proteomics identifies glucose transporter type 1 and prion protein as candidate biomarkers for colorectal adenoma-to-carcinoma progression.细胞表面蛋白质组学鉴定葡萄糖转运蛋白 1 和朊病毒蛋白为结直肠腺瘤癌变进展的候选生物标志物。
Gut. 2012 Jun;61(6):855-64. doi: 10.1136/gutjnl-2011-300511. Epub 2011 Sep 2.
9
KITENIN recruits Dishevelled/PKC delta to form a functional complex and controls the migration and invasiveness of colorectal cancer cells.激肽原酶招募散乱蛋白/蛋白激酶Cδ形成功能性复合物，并控制结肠癌细胞的迁移和侵袭能力。
Gut. 2009 Apr;58(4):509-19. doi: 10.1136/gut.2008.150938. Epub 2008 Jul 24.
10
A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation.两个Cbl的故事：c-Cbl与Cbl-b在表皮生长因子受体下调中的相互作用
Mol Cell Biol. 2008 May;28(9):3020-37. doi: 10.1128/MCB.01809-07. Epub 2008 Mar 3.